# Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

> **NCT03234465** · PHASE2 · TERMINATED · sponsor: **Oragenics, Inc.** · enrollment: 200 (actual)

## Conditions studied

- Oral Mucositis

## Interventions

- **BIOLOGICAL:** AG013
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03234465
- **Lead sponsor:** Oragenics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-18
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-07-13
- **Target enrollment:** 200 (ACTUAL)
- **Why stopped:** No efficacy could be demonstrated, sponsor decided to prematurely end the study.
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234465, "Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03234465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*